Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Julie McFadden has cared for over 100 patients in their final days. It serves a purpose — but not for the reason you think.

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression. Johnson & Johnson said patients who use ...

The historic dry spell that fueled the devastating Los Angeles wildfires is expected to end this weekend. Forecasters expect light rain and mountain snow on Saturday, ending 262 days and counting ...

The Mayor of Huntington Beach has introduced an initiative to make the community a “non-sanctuary city” as other cities in ...

Johnson & Johnson stock gapped down Wednesday after the health care giant issued light 2025 sales guidance, taking a hit from exchange rates.